Our top pick for
EZCORP Inc is a credit services business based in the US. EZCORP shares (EZPW) are listed on the NASDAQ and all prices are listed in US Dollars. EZCORP employs 5,900 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$7.91|
|52-week range||$4.34 - $8.79|
|50-day moving average||$7.38|
|200-day moving average||$6.49|
|Wall St. target price||$9.58|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.30|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-1.13%|
|1 month (2021-09-21)||8.21%|
|3 months (2021-07-21)||34.52%|
|6 months (2021-04-21)||54.49%|
|1 year (2020-10-20)||53.00%|
|2 years (2019-10-18)||36.61%|
|3 years (2018-10-19)||10.24|
|5 years (2016-10-20)||10.95|
Valuing EZCORP stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of EZCORP's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
EZCORP's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5058. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into EZCORP's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
EZCORP's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $55.3 million.
The EBITDA is a measure of a EZCORP's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$704 million|
|Operating margin TTM||3.5%|
|Gross profit TTM||$449.2 million|
|Return on assets TTM||1.25%|
|Return on equity TTM||-2.41%|
|Market capitalisation||$448.5 million|
TTM: trailing 12 months
There are currently 5.6 million EZCORP shares held short by investors – that's known as EZCORP's "short interest". This figure is 2.5% up from 5.4 million last month.
There are a few different ways that this level of interest in shorting EZCORP shares can be evaluated.
EZCORP's "short interest ratio" (SIR) is the quantity of EZCORP shares currently shorted divided by the average quantity of EZCORP shares traded daily (recently around 403159.27536232). EZCORP's SIR currently stands at 13.8. In other words for every 100,000 EZCORP shares traded daily on the market, roughly 13800 shares are currently held short.
However EZCORP's short interest can also be evaluated against the total number of EZCORP shares, or, against the total number of tradable EZCORP shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EZCORP's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 EZCORP shares in existence, roughly 100 shares are currently held short) or 0.1158% of the tradable shares (for every 100,000 tradable EZCORP shares, roughly 116 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against EZCORP.
Find out more about how you can short EZCORP stock.
We're not expecting EZCORP to pay a dividend over the next 12 months.
EZCORP's shares were split on a 3:1 basis on 11 December 2006. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your EZCORP shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for EZCORP shares which in turn could have impacted EZCORP's share price.
Over the last 12 months, EZCORP's shares have ranged in value from as little as $4.34 up to $8.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EZCORP's is 1.4429. This would suggest that EZCORP's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
EZCORP, Inc. provides pawn loans in the United States and Latin America. The company also sells merchandise, primarily collateral forfeited from pawn lending operations and pre-owned merchandise purchased from customers. It offers pawn loans, which are nonrecourse loans collateralized by tangible personal property, including jewelry, consumer electronics, tools, sporting goods, and musical instruments. In addition, the company offers Lana, a web-based engagement platform to manage pawn loans. As of September 30, 2020, it owned and operated 505 pawn stores in the United States; 368 pawn stores in Mexico; and 132 pawn stores in Guatemala, El Salvador, Honduras, and Peru. EZCORP, Inc.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.